CELLS EXHIBITING NEURONAL PROGENITOR CELL CHARACTERISTICS AND METHODS OF MAKING THEM

• US 20130071924A1
• Filed: 11/08/2012
• Published: 03/21/2013
• Est. Priority Date: 04/12/2004
• Status: Abandoned Application

• Current Assignee: Sanbio, Inc. (SanBio Co., Ltd.)
• Original Assignee: Sanbio, Inc. (SanBio Co., Ltd.)
• Inventors: Dezawa, Mari
• Application Number:
  US13/672,341
• Publication Number:
  US 20130071924A1
• Time in Patent Office: Days
• US Class Current: 435/353
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: C12N 2501/01 Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/13 Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/60 Transcription factors
• CPC Class Codes: C12N 2501/70 Enzymes
• CPC Class Codes: C12N 2501/727 Kinases (EC 2.7.)
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0619 Neurons

Abstract

Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.

Claims

1. A method for transdifferentiating marrow adherent stem cells (MASCs the method comprising incubating the MASCs with a glial regulating agent, wherein the glial regulating agent is a JAK/STAT inhibitor.

2. The method of claim 1, wherein the MASCs are selected from the group consisting of human marrow adherent stem cells, rat marrow adherent stem cells, mouse marrow adherent stem cells, primate marrow adherent stem cells, pig marrow adherent stem cells, cow marrow adherent stem cells, and sheep marrow adherent stem cells.

3. The method of claim 2, wherein the MASCs are human MASCs.

4. The method of claim 1, wherein the JAK/STAT inhibitor is an inhibitor of STAT1 or STAT3.

5. The method of claim 1, wherein the JAK/STAT inhibitor is a polypeptide.

6. The method of claim 5, wherein the incubation comprises transfection of the MASCs with a polynucleotide encoding the JAK/STAT inhibitor.

7. The method of claim 1, wherein the JAK/STAT inhibitor is 4-(4′

-hydroxyphenyl)amino-6,7-dimethoxyquinazoline.

8. The method of claim 1, wherein the JAK/STAT inhibitor is a RNAi molecule.

9. The method of claim 1, wherein the JAK/STAT inhibitor is an antisense oligonucleotide.

10. A method for inhibiting transdifferentiation of MASCs into glial cells, the method comprising incubating the MASCs with a glial regulating agent, wherein the glial regulating agent is a JAK/STAT inhibitor.

11. The method of claim 10, wherein the MASCs are selected from the group consisting of human marrow adherent stem cells, rat marrow adherent stem cells, mouse marrow adherent stem cells, primate marrow adherent stem cells, pig marrow adherent stem cells, cow marrow adherent stem cells, and sheep marrow adherent stem cells.

12. The method of claim 11, wherein the MASCs are human MASCs.

13. The method of claim 10, wherein the JAK/STAT inhibitor is an inhibitor of STAT1 or STAT3.

14. The method of claim 10, wherein the JAK/STAT inhibitor is a polypeptide.

15. The method of claim 14, wherein the incubation comprises transfection of the MASCs with a polynucleotide encoding the JAK/STAT inhibitor.

16. The method of claim 10, wherein the JAK/STAT inhibitor is 4-(4′

-hydroxyphenyl)amino-6,7-dimethoxyquinazoline.

17. The method of claim 10, wherein the JAK/STAT inhibitor is a RNAi molecule.

18. The method of claim 10, wherein the JAK/STAT inhibitor is an antisense oligonucleotide.

19. A composition comprising:

(a) marrow adherent stem cells (MASCs), and

(b) a JAK/STAT inhibitor.

20. The composition of claim 19, wherein the MASCs are selected from the group consisting of human marrow adherent stem cells, rat marrow adherent stem cells, mouse marrow adherent stem cells, primate marrow adherent stem cells, pig marrow adherent stem cells, cow marrow adherent stem cells, and sheep marrow adherent stem cells.

21. The composition of claim 20, wherein the MASCs are human MASCs.

22. The composition of claim 19, wherein the JAK/STAT inhibitor is an inhibitor of STAT1 or STAT3.

23. The composition of claim 19, wherein the JAK/STAT inhibitor is a polypeptide.

24. The composition of claim 19, wherein the JAK/STAT inhibitor is a polynucleotide encoding a polypeptide JAK/STAT inhibitor.

25. The composition of claim 19, wherein the JAK/STAT inhibitor is 4-(4′

-hydroxyphenyl)amino-6,7-dimethoxyquinazoline.

26. The composition of claim 19, wherein the JAK/STAT inhibitor is a RNAi molecule.

27. The composition of claim 19, wherein the JAK/STAT inhibitor is an antisense oligonucleotide.